Page 6 - Slides
P. 6
Disclosure of Commercial Support
• Potential for conflict(s) of interest:
• [Speaker/Faculty name] has received [payment/funding/etc.]
from [organization supporting program AND/OR organization
whose products(s) are being discussed in this program].
• Bayer benefits from the sale of a product that will be discussed
in this program: Darolutamide
*Health Canada approved on February 20, 2020
